April 9, 2010
As part of plan name’s ongoing quality improvement efforts, we periodically identify when members are taking
more than one medication belonging to the same class of drugs for a single health condition. As an example, the
plan name Pharmacy and Therapeutics (P&T) committee has identified patients who are taking two or more
atypical antipsychotic agents.
As the treating physician, you are best qualified to determine which agent and formulation are appropriate on a
However, for the safety of your patients, the P&T committee urges providers to evaluate all treatment programs
that include duplicative therapy in the same therapeutic class. Possible concerns associated with duplicative
The combined dosage level of medications
The increased potential for adverse events
Excessive treatment and patient out-of-pocket costs
Potentially additive effects of the patient’s over-the-counter medication ingredients
Instances of duplicative therapy can arise when prescribers are switching to an alternative therapy in a class and
the patient, due to a misunderstanding, continues to stay on the therapy(s) intended for discontinuance.
Please review the medications in the antipsychotic class listed in the table below.
Atypical Antipsychotic Agents
Preferred List agents
Nonpreferred List agents
Attached are information sheets designed to help your patients learn more about schizophrenia and bipolar
disorder. We have also included important information about the new Medicare Prescription Drug Benefit. Please
take the time to review this information with your patients and/or their caregivers, as appropriate.
We appreciate your continued support in our efforts to encourage quality care. If you have any questions, please
contact contact name, plan name / department name, at phone number and/or Web site address.
MEDICAL DIRECTOR NAME PHARMACY DIRECTOR NAME
Medical Director Pharmacy Director